Heart failure policy and practice in Europe
Heart failure policy and practice in Europe aims to support advocates with clear outline of policy issues and best practice in heart failure across 11 European countries.
Find out more
Heart failure and COVID‑19
With heart failure a high-risk pre-existing condition and heart damage a consequence of COVID-19, what does the pandemic mean for heart failure care?
Find out more
heart graphic

Helping advance meaningful policy change on heart failure

The Heart Failure Policy Network is an independent, multidisciplinary platform of healthcare professionals, advocacy groups and policymakers from across Europe.

We aim to raise awareness of the unmet needs surrounding heart failure and its care, and to help drive meaningful changes in policy and practice.

Find out more
Latest
How can the EU support Member States’ efforts to overcome challenges in heart failure policy?
2 March 2021

This video series examines the heart failure policy priorities different stakeholder would like to see, including healthcare professionals, patient advocates and policymakers.

Read article
Latest
The future of cardiovascular disease and heart failure policy
12 February 2021

Network Director, Ed Harding, examines the future of heart failure policy in Europe

Read article
Latest
HFPN round table explores opportunities for supportive heart failure policies from the EU
25 January 2021

On 9 December 2020, Mr Billy Kelleher MEP and the HFPN hosted a virtual round table on heart failure policy.

Read article
heart failure graphic
What is heart failure?

Affecting at least 15 million adults in Europe, heart failure is a common but complex clinical syndrome that occurs when the heart is unable to pump enough blood to meet body’s needs.

Its prevalence is expected to rise due to population ageing and improved survival rates for other long-term conditions, including cardiovascular diseases.

Find out more
The Heart Failure Policy Network is made possible with financial support from AstraZeneca, Vifor Pharma and Novartis Pharma. The content produced by the Network is non-promotional and not biased to any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members.